Bioventus Inc.
BVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $573,280 | $512,345 | $512,117 | $430,898 |
| % Growth | 11.9% | 0% | 18.8% | – |
| Cost of Goods Sold | $185,054 | $184,152 | $181,037 | $128,192 |
| Gross Profit | $388,226 | $328,193 | $331,080 | $302,706 |
| % Margin | 67.7% | 64.1% | 64.6% | 70.3% |
| R&D Expenses | $13,639 | $13,446 | $23,854 | $19,039 |
| G&A Expenses | $322,670 | $300,026 | $326,931 | $0 |
| SG&A Expenses | $327,092 | $303,879 | $332,134 | $254,253 |
| Sales & Mktg Exp. | $4,422 | $3,853 | $5,203 | $0 |
| Other Operating Expenses | $59,474 | $92,593 | $142,326 | $17,353 |
| Operating Expenses | $400,205 | $409,918 | $498,314 | $290,645 |
| Operating Income | -$11,979 | -$81,725 | -$167,234 | $12,061 |
| % Margin | -2.1% | -16% | -32.7% | 2.8% |
| Other Income/Exp. Net | -$37,147 | -$39,386 | -$21,791 | -$2,573 |
| Pre-Tax Income | -$49,126 | -$121,111 | -$189,025 | $9,488 |
| Tax Expense | -$5,293 | $85 | -$44,374 | -$1,966 |
| Net Income | -$33,542 | -$156,230 | -$158,704 | $19,375 |
| % Margin | -5.9% | -30.5% | -31% | 4.5% |
| EPS | -0.52 | -2.49 | -2.59 | -0.15 |
| % Growth | 79.1% | 3.9% | -1,626.7% | – |
| EPS Diluted | -0.52 | -2.49 | -2.59 | -0.15 |
| Weighted Avg Shares Out | 65,355 | 62,648 | 61,389 | 45,472 |
| Weighted Avg Shares Out Dil | 65,355 | 62,648 | 61,389 | 45,472 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $38,792 | $40,676 | $12,021 | $1,112 |
| Depreciation & Amortization | $49,555 | $57,365 | $55,398 | $34,875 |
| EBITDA | $39,221 | -$23,070 | -$121,606 | $45,475 |
| % Margin | 6.8% | -4.5% | -23.7% | 10.6% |